General features, pathogenesis, and laboratory diagnostics of autoimmune encephalitis

References

• Dalmau J, Graus F. Antibody-mediated encephalitis. Ropper AH, editor. N Engl J Med. 2018;378(9):840–851. doi: 10.1056/NEJMra1708712.
   PubMed Web of Science ®Google Scholar
• Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis: autoimmune encephalitis. Ann Neurol. 2018;83(1):166–177. doi: 10.1002/ana.25131.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97(2):839–887. doi: 10.1152/physrev.00010.2016.
   PubMed Web of Science ®Google Scholar
• Gastaldi M, Scaranzin S, Pietro B, et al. Paraneoplastic neurological syndromes: transitioning between the old and the new. Curr Oncol Rep. 2022;24(10):1237–1249. doi: 10.1007/s11912-022-01279-z.
   PubMed Web of Science ®Google Scholar
• Uy CE, Binks S, Irani SR. Autoimmune encephalitis: clinical spectrum and management. Pract Neurol. 2021;21(5):412–423. doi: 10.1136/practneurol-2020-002567.
   PubMedGoogle Scholar
• Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1014. doi: 10.1212/NXI.0000000000001014.
   PubMed Web of Science ®Google Scholar
• Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404. doi: 10.1016/S1474-4422(15)00401-9.
   PubMed Web of Science ®Google Scholar
• Corsellis JAN, Goldberg GJ, Norton AR. “limbic encephalitis” and its association with carcinoma. Brain. 1968;91(3):481–496. doi: 10.1093/brain/91.3.481.
   PubMed Web of Science ®Google Scholar
• Ding JB, Dongas J, Hu K, et al. Autoimmune limbic encephalitis: a review of clinicoradiological features and the challenges of diagnosis. Cureus [Internet]; 2021 [cited 2023 Mar 20]. Available from: https://www.cureus.com/articles/67206-autoimmune-limbic-encephalitis-a-review-of-clinicoradiological-features-and-the-challenges-of-diagnosis
   Google Scholar
• Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135–1140. doi: 10.1136/jnnp.2003.034447.
   PubMed Web of Science ®Google Scholar
• Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892–900. doi: 10.1002/ana.22307.
   PubMed Web of Science ®Google Scholar
• Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72(2):241–255. doi: 10.1002/ana.23577.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Tüzün E, Wu H, et al. Paraneoplastic anti- N -methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25–36. doi: 10.1002/ana.21050.
   PubMed Web of Science ®Google Scholar
• Al-Diwani A, Handel A, Townsend L, et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry. 2019;6(3):235–246. doi: 10.1016/S2215-0366(19)30001-X.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Armangué T, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045–1057. doi: 10.1016/S1474-4422(19)30244-3.
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–165. doi: 10.1016/S1474-4422(12)70310-1.
   PubMed Web of Science ®Google Scholar
• Bost C, Chanson E, Picard G, et al. Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies. J Neurol. 2018;265(10):2190–2200. doi: 10.1007/s00415-018-8970-0.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63–74. doi: 10.1016/S1474-4422(10)70253-2.
   PubMed Web of Science ®Google Scholar
• Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr Res. 2016;176(1):36–40. doi: 10.1016/j.schres.2014.10.007.
   PubMed Web of Science ®Google Scholar
• Spatola M, Petit-Pedrol M, Simabukuro MM, et al. Investigations in GABA a receptor antibody-associated encephalitis. Neurology. 2017;88(11):1012–1020. doi: 10.1212/WNL.0000000000003713.
   PubMed Web of Science ®Google Scholar
• Deng B, Cai M, Qiu Y, et al. MRI characteristics of autoimmune encephalitis with autoantibodies to GABAA receptor: a case series. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1158. doi: 10.1212/NXI.0000000000001158.
   PubMed Web of Science ®Google Scholar
• Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88(18):1736–1743. doi: 10.1212/WNL.0000000000003887.
   PubMed Web of Science ®Google Scholar
• Honorat JA, Komorowski L, Josephs KA, et al. IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e385. doi: 10.1212/NXI.0000000000000385.
   PubMed Web of Science ®Google Scholar
• Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13(6):575–586. doi: 10.1016/S1474-4422(14)70051-1.
   PubMed Web of Science ®Google Scholar
• Werner J, Jelcic I, Schwarz EI, et al. Anti-IgLON5 disease: a new bulbar-onset motor neuron mimic syndrome. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e962. doi: 10.1212/NXI.0000000000000962.
   PubMed Web of Science ®Google Scholar
• Gelpi E, Höftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol. 2016;132(4):531–543. doi: 10.1007/s00401-016-1591-8.
   PubMed Web of Science ®Google Scholar
• Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci. 2008;65(20):3168–3181. doi: 10.1007/s00018-008-8252-6.
   PubMed Web of Science ®Google Scholar
• Graus F, Keime-Guibert F, Reñe R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124(Pt 6):1138–1148. doi: 10.1093/brain/124.6.1138.
   PubMed Web of Science ®Google Scholar
• Li Q, Michel K, Annahazi A, et al. Anti-Hu antibodies activate enteric and sensory neurons. Sci Rep. 2016;6:38216. doi: 10.1038/srep38216.
   PubMed Web of Science ®Google Scholar
• Totland C, Aarskog NK, Eichler TW, et al. CDR2 antigen and Yo antibodies. Cancer Immunol Immunother. 2011;60(2):283–289. doi: 10.1007/s00262-010-0943-9.
   PubMed Web of Science ®Google Scholar
• Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol. 1983;14(6):609–613. doi: 10.1002/ana.410140603.
   PubMed Web of Science ®Google Scholar
• Déchelotte B, Muñiz-Castrillo S, Joubert B, et al. Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2020;7:e701. doi: 10.1212/NXI.0000000000000701.
   PubMed Web of Science ®Google Scholar
• Gong X, Tan M, Gao Y, et al. CRMP-5 interacts with actin to regulate neurite outgrowth. Mol Med Rep. 2016;13(2):1179–1185. doi: 10.3892/mmr.2015.4662.
   PubMed Web of Science ®Google Scholar
• Honnorat J, Antoine JC, Derrington E, et al. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 1996;61(3):270–278. doi: 10.1136/jnnp.61.3.270.
   PubMed Web of Science ®Google Scholar
• Sabater L, Saiz A, Dalmau J, et al. Pitfalls in the detection of CV2 (CRMP5) antibodies. J Neuroimmunol. 2016;290:80–83. doi: 10.1016/j.jneuroim.2015.11.009.
   PubMed Web of Science ®Google Scholar
• Jensen KB, Dredge BK, Stefani G, et al. Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron. 2000;25(2):359–371. doi: 10.1016/s0896-6273(00)80900-9.
   PubMed Web of Science ®Google Scholar
• Simard C, Vogrig A, Joubert B, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm. 2020;7:e699. doi: 10.1212/NXI.0000000000000699.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127(Pt 8):1831–1844. doi: 10.1093/brain/awh203.
   PubMed Web of Science ®Google Scholar
• Wigge P, McMahon HT. The amphiphysin family of proteins and their role in endocytosis at the synapse. Trends Neurosci. 1998;21(8):339–344. doi: 10.1016/s0166-2236(98)01264-8.
   PubMed Web of Science ®Google Scholar
• Antoine JC, Absi L, Honnorat J, et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol. 1999;56(2):172–177. doi: 10.1001/archneur.56.2.172.
   PubMedGoogle Scholar
• Gadoth A, Kryzer TJ, Fryer J, et al. Microtubule-associated protein 1B: novel paraneoplastic biomarker: MAP1B IgG. Ann Neurol. 2017;81(2):266–277. doi: 10.1002/ana.24872.
   PubMed Web of Science ®Google Scholar
• Stevanovic M, Drakulic D, Lazic A, et al. SOX transcription factors as important regulators of neuronal and glial differentiation during nervous system development and adult neurogenesis. Front. Mol. Neurosci. 2021;14:654031. doi: 10.3389/fnmol.2021.654031.
   PubMed Web of Science ®Google Scholar
• Sabater L, Titulaer M, Saiz A, et al. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70(12):924–928. doi: 10.1212/01.wnl.0000281663.81079.24.
   PubMed Web of Science ®Google Scholar
• Ruiz-García R, Martínez-Hernández E, García-Ormaechea M, et al. Caveats and pitfalls of SOX1 autoantibody testing with a commercial line blot assay in paraneoplastic neurological investigations. Front Immunol. 2019;10:769. doi: 10.3389/fimmu.2019.00769.
   PubMed Web of Science ®Google Scholar
• Vogrig A, Péricart S, Pinto A-L, et al. Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. Brain Commun. 2021;3(3):fcab185. doi: 10.1093/braincomms/fcab185.
   PubMedGoogle Scholar
• Basal E, Zalewski N, Kryzer TJ, et al. Paraneoplastic neuronal intermediate filament autoimmunity. Neurology. 2018;91(18):e1677–e1689. doi: 10.1212/WNL.0000000000006435.
   PubMed Web of Science ®Google Scholar
• Zekeridou A, Kryzer T, Guo Y, et al. Phosphodiesterase 10A IgG: a novel biomarker of paraneoplastic neurologic autoimmunity. Neurology. 2019;93(8):e815–e822. doi: 10.1212/WNL.0000000000007971.
   PubMed Web of Science ®Google Scholar
• Zekeridou A, Yang B, Lennon VA, et al. Anti-neuronal nuclear antibody 3 autoimmunity targets dachshund homolog 1. Ann Neurol. 2022;91(5):670–675. doi: 10.1002/ana.26320.
   PubMed Web of Science ®Google Scholar
• Eiraku M, Hirata Y, Takeshima H, et al. Delta/notch-like epidermal growth factor (EGF)-related receptor, a novel EGF-like repeat-containing protein targeted to dendrites of developing and adult central nervous system neurons. J Biol Chem. 2002;277(28):25400–25407. doi: 10.1074/jbc.M110793200.
   PubMed Web of Science ®Google Scholar
• Greene M, Lai Y, Baella N, et al. Antibodies to delta/notch-like epidermal growth factor–related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma. JAMA Neurol. 2014;71(8):1003–1008. doi: 10.1001/jamaneurol.2014.999.
   PubMed Web of Science ®Google Scholar
• Probst C, Komorowski L, de Graaff E, et al. Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e68. doi: 10.1212/NXI.0000000000000068.
   PubMedGoogle Scholar
• van Coevorden-Hameete MH, van Beuningen SFB, Perrenoud M, et al. Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes. Ann Clin Transl Neurol. 2017;4(9):680–686. doi: 10.1002/acn3.396.
   PubMed Web of Science ®Google Scholar
• Honorat JA, Lopez-Chiriboga AS, Kryzer TJ, et al. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG. Neurology. 2019;93(10):e954–e963. doi: 10.1212/WNL.0000000000008061.
   PubMed Web of Science ®Google Scholar
• Miske R, Scharf M, Stark P, et al. Autoantibodies against the Purkinje cell protein RGS8 in paraneoplastic cerebellar syndrome. Neurol Neuroimmunol Neuroinflamm. 2021;8:e987. doi: 10.1212/NXI.0000000000000987.
   PubMed Web of Science ®Google Scholar
• Muñiz-Castrillo S, Hedou JJ, Ambati A, et al. Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. Brain. 2021;144(9):2709–2721. doi: 10.1093/brain/awab153.
   PubMedGoogle Scholar
• Fenalti G, Buckle AM. Structural biology of the GAD autoantigen. Autoimmun Rev. 2010;9(3):148–152. doi: 10.1016/j.autrev.2009.05.003.
   PubMed Web of Science ®Google Scholar
• Graus F, Saiz A, Dalmau J. GAD antibodies in neurological disorders—insights and challenges. Nat Rev Neurol. 2020;16(7):353–365. doi: 10.1038/s41582-020-0359-x.
   PubMed Web of Science ®Google Scholar
• Do L-D, Moritz CP, Muñiz-Castrillo S, et al. Argonaute autoantibodies as biomarkers in autoimmune neurologic diseases. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1032. doi: 10.1212/NXI.0000000000001032.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang KKW. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364–374. doi: 10.1016/j.tins.2015.04.003.
   PubMed Web of Science ®Google Scholar
• Fang B, McKeon A, Hinson SR, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol. 2016;73(11):1297–1307. doi: 10.1001/jamaneurol.2016.2549.
   PubMed Web of Science ®Google Scholar
• Bataller L, Wade DF, Graus F, et al. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology. 2004;62(5):778–782. doi: 10.1212/01.wnl.0000113749.77217.01.
   Google Scholar
• Hinson SR, Honorat JA, Grund EM, et al. Septin-5 and - 7-IgGs : neurologic, serologic, and pathophysiologic characteristics. Ann Neurol. 2022;92(6):1090–1101. doi: 10.1002/ana.26482.
   PubMed Web of Science ®Google Scholar
• Hansen KB, Yi F, Perszyk RE, et al. NMDA receptors in the central nervous system. In: Burnashev N, Szepetowski P, editors. NMDA receptors [Internet]. New York, NY: Springer; 2017 [cited 2023 Mar 21]. p. 1–80. Available from: https://doi.org/10.1007/978-1-4939-7321-7_1
   Google Scholar
• McCracken L, Zhang J, Greene M, et al. Improving the antibody-based evaluation of autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2017;4(6):e404. doi: 10.1212/NXI.0000000000000404.
   PubMed Web of Science ®Google Scholar
• Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014;13(2):167–177. doi: 10.1016/S1474-4422(13)70282-5.
   PubMed Web of Science ®Google Scholar
• Baudin P, Cousyn L, Navarro V. The LGI1 protein: molecular structure, physiological functions and disruption-related seizures. Cell Mol Life Sci. 2021;79(1):16. doi: 10.1007/s00018-021-04088-y.
   PubMed Web of Science ®Google Scholar
• van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology. 2016;87(14):1449–1456. doi: 10.1212/WNL.0000000000003173.
   PubMed Web of Science ®Google Scholar
• Saint-Martin M, Pieters A, Déchelotte B, et al. Impact of anti-CASPR2 autoantibodies from patients with autoimmune encephalitis on CASPR2/TAG-1 interaction and Kv1 expression. J Autoimmun. 2019;103:102284. doi: 10.1016/j.jaut.2019.05.012.
   PubMed Web of Science ®Google Scholar
• van Sonderen A, Petit-Pedrol M, Dalmau J, et al. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol. 2017;13(5):290–301. doi: 10.1038/nrneurol.2017.43.
   PubMed Web of Science ®Google Scholar
• Burgos CF, Yévenes GE, Aguayo LG. Structure and pharmacologic modulation of inhibitory glycine receptors. Mol Pharmacol. 2016;90(3):318–325. doi: 10.1124/mol.116.105726.
   PubMed Web of Science ®Google Scholar
• Carvajal-González A, Leite MI, Waters P, et al. Glycine receptor antibodies in Perm and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137(Pt 8):2178–2192. doi: 10.1093/brain/awu142.
   PubMed Web of Science ®Google Scholar
• Sigel E, Steinmann ME. Structure, function, and modulation of GABAA receptors. J Biol Chem. 2012;287(48):40224–40231. doi: 10.1074/jbc.R112.386664.
   PubMed Web of Science ®Google Scholar
• Terunuma M. Diversity of structure and function of GABAB receptors: a complexity of GABAB-mediated signaling. Proc Jpn Acad Ser B Phys Biol Sci. 2018;94(10):390–411. doi: 10.2183/pjab.94.026.
   PubMed Web of Science ®Google Scholar
• Hoftberger R, Titulaer MJ, Sabater L, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81(17):1500–1506. doi: 10.1212/WNL.0b013e3182a9585f.
   PubMed Web of Science ®Google Scholar
• Ruiz-García R, Muñoz-Sánchez G, Naranjo L, et al. Limitations of a commercial assay as diagnostic test of autoimmune encephalitis. Front Immunol. 2021;12:691536. doi: 10.3389/fimmu.2021.691536.
   PubMed Web of Science ®Google Scholar
• Lancaster E, Lai M, Peng X, et al. Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9(1):67–76. doi: 10.1016/S1474-4422(09)70324-2.
   PubMed Web of Science ®Google Scholar
• Hoftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology. 2015;84(24):2403–2412. doi: 10.1212/WNL.0000000000001682.
   PubMed Web of Science ®Google Scholar
• Spatola M, Sabater L, Planagumà J, et al. Encephalitis with mGluR5 antibodies: symptoms and antibody effects. Neurology. 2018;90(22):e1964–e1972. doi: 10.1212/WNL.0000000000005614.
   PubMed Web of Science ®Google Scholar
• Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol. 2013;73(1):120–128. doi: 10.1002/ana.23756.
   PubMed Web of Science ®Google Scholar
• Martel JC, Gatti McArthur S. Dopamine receptor subtypes, physiology and pharmacology: new ligands and concepts in schizophrenia. Front Pharmacol. 2020;11:1003. doi: 10.3389/fphar.2020.01003.
   PubMed Web of Science ®Google Scholar
• Dale RC, Merheb V, Pillai S, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012;135(Pt 11):3453–3468. doi: 10.1093/brain/aws256.
   PubMedGoogle Scholar
• Gresa-Arribas N, Planagumà J, Petit-Pedrol M, et al. Human neurexin-3α antibodies associate with encephalitis and alter synapse development. Neurology. 2016;86(24):2235–2242. doi: 10.1212/WNL.0000000000002775.
   PubMed Web of Science ®Google Scholar
• Pandya NJ, Klaassen RV, van der Schors RC, et al. Group 1 metabotropic glutamate receptors 1 and 5 form a protein complex in mouse hippocampus and cortex. Proteomics. 2016;16(20):2698–2705. doi: 10.1002/pmic.201500400.
   PubMed Web of Science ®Google Scholar
• Spatola M, Petit Pedrol M, Maudes E, et al. Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. Neurology. 2020;95(22):e3012–e3025. doi: 10.1212/WNL.0000000000010854.
   PubMed Web of Science ®Google Scholar
• Abarkan M, Gaitan J, Lebreton F, et al. The glutamate receptor GluK2 contributes to the regulation of glucose homeostasis and its deterioration during aging. Mol Metab. 2019;30:152–160. doi: 10.1016/j.molmet.2019.09.011.
   PubMed Web of Science ®Google Scholar
• Landa J, Guasp M, Míguez-Cabello F, et al. Encephalitis with autoantibodies against the glutamate kainate receptors GluK2. Ann Neurol. 2021;90(1):101–117. doi: 10.1002/ana.26098.
   PubMed Web of Science ®Google Scholar
• Landa J, Guasp M, Petit-Pedrol M, et al. Seizure-related 6 homolog like 2 autoimmunity: neurologic syndrome and antibody effects. Neurol Neuroimmunol Neuroinflamm. 2021;8:e916. doi: 10.1212/NXI.0000000000000916.
   PubMed Web of Science ®Google Scholar
• Lancaster E. The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol. 2016;12(1):1–13. doi: 10.3988/jcn.2016.12.1.1.
   PubMed Web of Science ®Google Scholar
• Kelley BP, Patel SC, Marin HL, et al. Autoimmune encephalitis: pathophysiology and imaging review of an overlooked diagnosis. AJNR Am J Neuroradiol. 2017;38(6):1070–1078. doi: 10.3174/ajnr.A5086.
   PubMed Web of Science ®Google Scholar
• Blinder T, Lewerenz J. Cerebrospinal fluid findings in patients with autoimmune encephalitis—a systematic analysis. Front Neurol. 2019;10:804. doi: 10.3389/fneur.2019.00804.
   PubMed Web of Science ®Google Scholar
• Zhang T, Duan Y, Ye J, et al. Brain MRI characteristics of patients with anti-N-methyl-D-aspartate receptor encephalitis and their associations with 2-year clinical outcome. AJNR Am J Neuroradiol. 2018;39(5):824–829. doi: 10.3174/ajnr.A5593.
   PubMed Web of Science ®Google Scholar
• Armangue T, Santamaria J, Dalmau J. When a serum test overrides the clinical assessment. Neurology. 2015;84(13):1379–1381. doi: 10.1212/WNL.0000000000001425.
   PubMed Web of Science ®Google Scholar
• Graus F, Escudero D, Oleaga L, et al. Syndrome and outcome of antibody-negative limbic encephalitis. Eur J Neurol. 2018;25(8):1011–1016. doi: 10.1111/ene.13661.
   PubMed Web of Science ®Google Scholar
• Muñiz-Castrillo S, Vogrig A, Honnorat J. Associations between HLA and autoimmune neurological diseases with autoantibodies. Auto Immun Highlights. 2020;11(1):2. doi: 10.1186/s13317-019-0124-6.
   PubMed Web of Science ®Google Scholar
• Seldin MF. The genetics of human autoimmune disease: a perspective on progress in the field and future directions. J Autoimmun. 2015;64:1–12. doi: 10.1016/j.jaut.2015.08.015.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Brilot F, Irani SR, et al. Origins and immunopathogenesis of autoimmune central nervous system disorders. Nat Rev Neurol. 2023;19(3):172–190. doi: 10.1038/s41582-023-00776-4.
   PubMed Web of Science ®Google Scholar
• Kim T-J, Lee S-T, Moon J, et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes: HLA subtypes in anti-LGI1 encephalitis. Ann Neurol. 2017;81(2):183–192. doi: 10.1002/ana.24860.
   PubMed Web of Science ®Google Scholar
• Mueller SH, Färber A, Prüss H, et al. Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis: GWAS. Ann Neurol. 2018;83(4):863–869. doi: 10.1002/ana.25216.
   PubMed Web of Science ®Google Scholar
• van Sonderen A, Roelen DL, Stoop JA, et al. Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4: anti-LGI1 encephalitis. Ann Neurol. 2017;81(2):193–198. doi: 10.1002/ana.24858.
   PubMed Web of Science ®Google Scholar
• Muñiz-Castrillo S, Haesebaert J, Thomas L, et al. Clinical and prognostic value of immunogenetic characteristics in anti-LGI1 encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8:e974. doi: 10.1212/NXI.0000000000000974.
   PubMed Web of Science ®Google Scholar
• Peris Sempere V, Muñiz-Castrillo S, Ambati A, et al. Human leukocyte antigen association study reveals DRB1*04:02 effects additional to DRB1*07:01 in anti-LGI1 encephalitis. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1140. doi: 10.1212/NXI.0000000000001140.
   PubMed Web of Science ®Google Scholar
• Binks S, Varley J, Lee W, et al. Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain. 2018;141(8):2263–2271. doi: 10.1093/brain/awy109.
   PubMedGoogle Scholar
• Muñiz-Castrillo S, Joubert B, Elsensohn M-H, et al. Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features. J Neurol Neurosurg Psychiatry. 2020;91(10):1076–1084. doi: 10.1136/jnnp-2020-323226.
   PubMed Web of Science ®Google Scholar
• Gaig C, Ercilla G, Daura X, et al. HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. Neurol Neuroimmunol Neuroinflamm. 2019;6:e605. doi: 10.1212/NXI.0000000000000605.
   PubMed Web of Science ®Google Scholar
• Tietz AK, Angstwurm K, Baumgartner T, et al. Genome-wide association study identifies 2 new loci associated with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1085. doi: 10.1212/NXI.0000000000001085.
   PubMed Web of Science ®Google Scholar
• de Graaf MT, de Beukelaar JWK, Haasnoot GW, et al. HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. J Neuroimmunol. 2010;226(1-2):147–149. doi: 10.1016/j.jneuroim.2010.05.035.
   PubMed Web of Science ®Google Scholar
• Strippel C, Herrera-Rivero M, Wendorff M, et al. A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies. Brain. 2023;146(3):977–990. doi: 10.1093/brain/awac119.
   PubMedGoogle Scholar
• Venkatesan A, Benavides DR. Autoimmune encephalitis and its relation to infection. Curr Neurol Neurosci Rep. 2015;15(3):3. doi: 10.1007/s11910-015-0529-1.
   PubMed Web of Science ®Google Scholar
• Höftberger R, Armangue T, Leypoldt F, et al. Clinical neuropathology practice guide 4-2013: post-herpes simplex encephalitis: n-methyl-daspartate receptor antibodies are part of the problem. Clin Neuropathol. 2013;32(4):251–254. doi: 10.5414/np300666.
   PubMed Web of Science ®Google Scholar
• Armangue T, Spatola M, Vlagea A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17(9):760–772. doi: 10.1016/S1474-4422(18)30244-8.
   PubMed Web of Science ®Google Scholar
• Sun B, Ramberger M, O'Connor KC, et al. The B cell immunobiology that underlies CNS autoantibody-mediated diseases. Nat Rev Neurol. 2020;16(9):481–492. doi: 10.1038/s41582-020-0381-z.
   PubMed Web of Science ®Google Scholar
• Pilotto A, Masciocchi S, Volonghi I, et al. Clinical presentation and outcomes of SARS-CoV-2 related encephalitis: the ENCOVID multicentre study. J Infect Dis. 2021;223(1):28–37. doi: 10.1093/infdis/jiaa609.
   Google Scholar
• Manzano GS, McEntire CRS, Martinez-Lage M, et al. Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19: systematic review and meta-synthesis. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1080. doi: 10.1212/NXI.0000000000001080.
   PubMed Web of Science ®Google Scholar
• Franke C, Ferse C, Kreye J, et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2021;93:415–419. doi: 10.1016/j.bbi.2020.12.022.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–692. doi: 10.1158/1078-0432.CCR-14-1860.
   PubMed Web of Science ®Google Scholar
• Manley GT, Smitt PS, Dalmau J, et al. Hu antigens: reactivity with hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol. 1995;38(1):102–110. doi: 10.1002/ana.410380117.
   PubMed Web of Science ®Google Scholar
• Al-Diwani A, Theorell J, Damato V, et al. Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis. Brain. 2022;145(8):2742–2754. doi: 10.1093/brain/awac088.
   PubMed Web of Science ®Google Scholar
• Simabukuro MM, Petit-Pedrol M, Castro LH, et al. GABA a receptor and LGI1 antibody encephalitis in a patient with thymoma. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e73. doi: 10.1212/NXI.0000000000000073.
   PubMedGoogle Scholar
• Alexopoulos H, Dagklis IE, Akrivou S, et al. Autoimmune encephalitis with GABA B antibodies, thymoma, and GABA B receptor thymic expression. Neurol Neuroimmunol Neuroinflamm. 2014;1(4):e39. doi: 10.1212/NXI.0000000000000039.
   PubMedGoogle Scholar
• Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. OncoImmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384.
   PubMed Web of Science ®Google Scholar
• Peter E, Treilleux I, Wucher V, et al. Immune and genetic signatures of breast carcinomas triggering anti-Yo–associated paraneoplastic cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm. 2022;9:e200015. doi: 10.1212/NXI.0000000000200015.
   PubMed Web of Science ®Google Scholar
• Small M, Treilleux I, Couillault C, et al. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol. 2018;135(4):569–579. doi: 10.1007/s00401-017-1802-y.
   PubMed Web of Science ®Google Scholar
• Chefdeville A, Treilleux I, Mayeur M-E, et al. Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis. Acta Neuropathol Commun. 2019;7(1):38. doi: 10.1186/s40478-019-0693-7.
   PubMedGoogle Scholar
• Jacob JB, Jacob MK, Parajuli P. Review of immune checkpoint inhibitors in immuno-oncology. Adv Pharmacol. 2021;91:111–139. doi: 10.1016/bs.apha.2021.01.002.
   Google Scholar
• Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. doi: 10.1038/s41467-020-17670-y.
   PubMed Web of Science ®Google Scholar
• Manenti S, Orrico M, Masciocchi S, et al. PD-1/PD-L axis in neuroinflammation: new insights. Front Neurol. 2022;13:877936. doi: 10.3389/fneur.2022.877936.
   PubMed Web of Science ®Google Scholar
• Velasco R, Villagrán M, Jové M, et al. Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol. 2021;78(7):864–873. doi: 10.1001/jamaneurol.2021.0249.
   PubMed Web of Science ®Google Scholar
• Farina A, Villagrán-García M, Ciano-Petersen NL, et al. Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200058. doi: 10.1212/NXI.0000000000200058.
   PubMed Web of Science ®Google Scholar
• Vogrig A, Fouret M, Joubert B, et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2019;6:e604. doi: 10.1212/NXI.0000000000000604.
   PubMed Web of Science ®Google Scholar
• Manson G, Maria ATJ, Poizeau F, et al. Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. J Immunother Cancer. 2019;7(1):337. doi: 10.1186/s40425-019-0821-8.
   PubMed Web of Science ®Google Scholar
• Raibagkar P, Ho D, Gunturu KS, et al. Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: case report and review of literature. J Neuroimmunol. 2020;341:577184. doi: 10.1016/j.jneuroim.2020.577184.
   PubMed Web of Science ®Google Scholar
• Malter MP, Elger CE, Surges R. Diagnostic value of CSF findings in antibody-associated limbic and anti-NMDAR-encephalitis. Seizure. 2013;22(2):136–140. doi: 10.1016/j.seizure.2012.12.013.
   PubMed Web of Science ®Google Scholar
• Lehmann-Horn K, Irani SR, Wang S, et al. Intrathecal B-cell activation in LGI1 antibody encephalitis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e669. doi: 10.1212/NXI.0000000000000669.
   PubMed Web of Science ®Google Scholar
• Moscato EH, Peng X, Jain A, et al. Acute mechanisms underlying antibody effects in anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;76(1):108–119. doi: 10.1002/ana.24195.
   PubMed Web of Science ®Google Scholar
• Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30(17):5866–5875. doi: 10.1523/JNEUROSCI.0167-10.2010.
   PubMed Web of Science ®Google Scholar
• Carvajal-González A, Jacobson L, Clover L, et al. Systemic delivery of human GlyR IgG antibody induces GlyR internalization into motor neurons of brainstem and spinal cord with motor dysfunction in mice. Neuropathol Appl Neurobiol. 2021;47(2):316–327. doi: 10.1111/nan.12666.
   PubMed Web of Science ®Google Scholar
• Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65(4):424–434. doi: 10.1002/ana.21589.
   PubMed Web of Science ®Google Scholar
• Peng X, Hughes EG, Moscato EH, et al. Cellular plasticity induced by anti–α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol. 2015;77(3):381–398. doi: 10.1002/ana.24293.
   PubMed Web of Science ®Google Scholar
• Pettingill P, Kramer HB, Coebergh JA. Antibodies to GABAA receptor a1 and g2 subunits. Neurology. 2015;84(12):1233–1241. doi: 10.1212/WNL.0000000000001326.
   Google Scholar
• Landa J, Gaig C, Plagumà J, et al. Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration. Ann Neurol. 2020;88(5):1023–1027. doi: 10.1002/ana.25857.
   PubMed Web of Science ®Google Scholar
• Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology. 2011;77(6):589–593. doi: 10.1212/WNL.0b013e318228c136.
   PubMed Web of Science ®Google Scholar
• Zrzavy T, Endmayr V, Bauer J, et al. Neuropathological variability within a spectrum of NMDAR-encephalitis. Ann Neurol. 2021;90(5):725–737. doi: 10.1002/ana.26223.
   PubMed Web of Science ®Google Scholar
• Tüzün E, Zhou L, Baehring JM, et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. 2009;118(6):737–743. doi: 10.1007/s00401-009-0582-4.
   PubMed Web of Science ®Google Scholar
• Klang A, Schmidt P, Kneissl S, et al. IgG and complement deposition and neuronal loss in cats and humans with epilepsy and voltage-gated potassium channel complex antibodies. J Neuropathol Exp Neurol. 2014;73(5):403–413. doi: 10.1097/NEN.0000000000000063.
   PubMed Web of Science ®Google Scholar
• Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. 2012;135(Pt 5):1622–1638. doi: 10.1093/brain/aws082.
   PubMed Web of Science ®Google Scholar
• Körtvelyessy P, Bauer J, Stoppel CM, et al. Complement-associated neuronal loss in a patient with CASPR2 antibody–associated encephalitis. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e75. doi: 10.1212/NXI.0000000000000075.
   PubMedGoogle Scholar
• Räuber S, Schroeter CB, Strippel C, et al. Cerebrospinal fluid proteomics indicates immune dysregulation and neuronal dysfunction in antibody associated autoimmune encephalitis. J Autoimmun. 2023;135:102985. doi: 10.1016/j.jaut.2022.102985.
   PubMed Web of Science ®Google Scholar
• Huijbers MG, Querol LA, Niks EH, et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol. 2015;22(8):1151–1161. doi: 10.1111/ene.12758.
   PubMed Web of Science ®Google Scholar
• Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol. 2020;16(12):702–714. doi: 10.1038/s41584-020-0500-7.
   PubMed Web of Science ®Google Scholar
• Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology. 2002;105(1):9–19. doi: 10.1046/j.0019-2805.2001.01341.x.
   PubMed Web of Science ®Google Scholar
• Ohkawa T, Fukata Y, Yamasaki M, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci. 2013;33(46):18161–18174. doi: 10.1523/JNEUROSCI.3506-13.2013.
   PubMed Web of Science ®Google Scholar
• Joubert B, Petit-Pedrol M, Planagumà J, et al. Human CASPR2 antibodies reversibly alter memory and the CASPR2 protein complex. Ann Neurol. 2022;91(6):801–813. doi: 10.1002/ana.26345.
   PubMed Web of Science ®Google Scholar
• Patterson KR, Dalmau J, Lancaster E. Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia: caspr2 antibody mechanisms. Ann Neurol. 2018;83(1):40–51. doi: 10.1002/ana.25120.
   PubMed Web of Science ®Google Scholar
• Mikasova L, De Rossi P, Bouchet D, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012;135(Pt 5):1606–1621. doi: 10.1093/brain/aws092.
   PubMed Web of Science ®Google Scholar
• Planagumà J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015;138(Pt 1):94–109. doi: 10.1093/brain/awu310.
   PubMed Web of Science ®Google Scholar
• Crisp SJ, Dixon CL, Jacobson L, et al. Glycine receptor autoantibodies disrupt inhibitory neurotransmission. Brain. 2019;142(11):3398–3410. doi: 10.1093/brain/awz297.
   PubMedGoogle Scholar
• Piepgras J, Höltje M, Michel K, et al. Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons. Neurology. 2015;85(10):890–897. doi: 10.1212/WNL.0000000000001907.
   PubMed Web of Science ®Google Scholar
• Ryding M, Gamre M, Nissen MS, et al. Neurodegeneration induced by anti-IgLON5 antibodies studied in induced pluripotent stem cell-derived human neurons. Cells. 2021;10:837. doi: 10.3390/cells10040837.
   PubMed Web of Science ®Google Scholar
• Giannoccaro MP, Wright SK, Vincent A. In vivo mechanisms of antibody-mediated neurological disorders: animal models and potential implications. Front Neurol. 2019;10:1394. doi: 10.3389/fneur.2019.01394.
   PubMed Web of Science ®Google Scholar
• Blome R, Bach W, Guli X, et al. Differentially altered NMDAR dependent and independent long-term potentiation in the CA3 subfield in a model of anti-NMDAR encephalitis. Front Synaptic Neurosci. 2018;10:26. doi: 10.3389/fnsyn.2018.00026.
   PubMed Web of Science ®Google Scholar
• Würdemann T, Kersten M, Tokay T, et al. Stereotactic injection of cerebrospinal fluid from anti-NMDA receptor encephalitis into rat dentate gyrus impairs NMDA receptor function. Brain Res. 2016;1633:10–18. doi: 10.1016/j.brainres.2015.12.027.
   PubMed Web of Science ®Google Scholar
• Kersten M, Rabbe T, Blome R, et al. Novel object recognition in rats with NMDAR dysfunction in CA1 after stereotactic injection of anti-NMDAR encephalitis cerebrospinal fluid. Front Neurol. 2019;10:586. doi: 10.3389/fneur.2019.00586.
   PubMed Web of Science ®Google Scholar
• Radosevic M, Planagumà J, Mannara F, et al. Allosteric modulation of NMDARs reverses patients’ autoantibody effects in mice. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1122. doi: 10.1212/NXI.0000000000001122.
   PubMed Web of Science ®Google Scholar
• Petit-Pedrol M, Sell J, Planagumà J, et al. LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain [Internet]. 2018 [cited 2023 Mar 20]. doi: 10.1093/brain/awy253
   Google Scholar
• Giannoccaro MP, Menassa DA, Jacobson L, et al. Behaviour and neuropathology in mice injected with human contactin-associated protein 2 antibodies. Brain. 2019;142(7):2000–2012. doi: 10.1093/brain/awz119.
   PubMedGoogle Scholar
• Pan H, Oliveira B, Saher G, et al. Uncoupling the widespread occurrence of anti-NMDAR1 autoantibodies from neuropsychiatric disease in a novel autoimmune model. Mol Psychiatry. 2019;24(10):1489–1501. doi: 10.1038/s41380-017-0011-3.
   PubMed Web of Science ®Google Scholar
• Jones BE, Tovar KR, Goehring A, et al. Autoimmune receptor encephalitis in mice induced by active immunization with conformationally stabilized holoreceptors. Sci Transl Med. 2019;11:eaaw0044. doi: 10.1126/scitranslmed.aaw0044.
   PubMed Web of Science ®Google Scholar
• Duong SL, Prüss H. Molecular disease mechanisms of human antineuronal monoclonal autoantibodies. Trends Mol Med. 2023;29(1):20–34. doi: 10.1016/j.molmed.2022.09.011.
   PubMed Web of Science ®Google Scholar
• Sharma R, Al-Saleem FH, Panzer J, et al. Monoclonal antibodies from a patient with anti-NMDA receptor encephalitis. Ann Clin Transl Neurol. 2018;5(8):935–951. doi: 10.1002/acn3.592.
   PubMed Web of Science ®Google Scholar
• Parray HA, Shukla S, Samal S, et al. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. Int Immunopharmacol. 2020;85:106639. doi: 10.1016/j.intimp.2020.106639.
   PubMed Web of Science ®Google Scholar
• Kreye J, Wright SK, van Casteren A, et al. Encephalitis patient-derived monoclonal GABAA receptor antibodies cause epileptic seizures. J Exp Med. 2021; 218(11):e20210012. doi: 10.1084/jem.20210012.
   Google Scholar
• Ly L-T, Kreye J, Jurek B, et al. Affinities of human NMDA receptor autoantibodies: implications for disease mechanisms and clinical diagnostics. J Neurol. 2018;265(11):2625–2632. doi: 10.1007/s00415-018-9042-1.
   PubMed Web of Science ®Google Scholar
• Ramberger M, Berretta A, Tan JMM, et al. Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms. Brain. 2020;143(6):1731–1745. doi: 10.1093/brain/awaa104.
   PubMedGoogle Scholar
• Graus F, Ilia I, Agusti M, et al. Effect of intraventricular injection of an anti-Purkinjc cell antibody (anti-Yo) in a Guinea pig model. J Neurol Sci. 1991;106(1):82–87. doi: 10.1016/0022-510x(91)90198-g.
   Google Scholar
• Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci U S A. 1996;93(10):4529–4536. doi: 10.1073/pnas.93.10.4529.
   PubMed Web of Science ®Google Scholar
• Benyahia B, Liblau R, Merle-Bé Ral H, et al. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol. 1999;45(2):162–167. doi: 10.1002/1531-8249(199902)45:2<162::AID-ANA5>3.0.CO;2-R.
   PubMed Web of Science ®Google Scholar
• Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. 2000;47(1):9–17. doi: 10.1002/1531-8249(200001)47:1<9::AID-ANA5>3.0.CO;2-I.
   PubMed Web of Science ®Google Scholar
• Roberts WK, Deluca IJ, Thomas A, et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest. 2009;119(7):2042–2051. doi: 10.1172/JCI36131.
   PubMed Web of Science ®Google Scholar
• Rousseau A, Benyahia B, Dalmau J, et al. T cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol. 2005;71(3):231–236. doi: 10.1007/s11060-004-1723-1.
   PubMed Web of Science ®Google Scholar
• McKeon A, Pittock SJ. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol. 2011;122(4):381–400. doi: 10.1007/s00401-011-0876-1.
   PubMed Web of Science ®Google Scholar
• Bauer J, Bien CG. Neuropathology of autoimmune encephalitides. Handb Clin Neurol. 2016;133:107–120. doi: 10.1016/B978-0-444-63432-0.00007-4.
   Google Scholar
• Pellkofer H, Schubart AS, Höftberger R, et al. Modelling paraneoplastic CNS disease: t -cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain. 2004;127(Pt 8):1822–1830. doi: 10.1093/brain/awh205.
   PubMedGoogle Scholar
• Blachère NE, Orange DE, Santomasso BD, et al. T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation: cellular immune response. Eur J Immunol. 2014;44(11):3240–3251. doi: 10.1002/eji.201444624.
   PubMed Web of Science ®Google Scholar
• Gebauer C, Pignolet B, Yshii L, et al. CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model. OncoImmunology. 2017;6(2):e1260212. doi: 10.1080/2162402X.2016.1260212.
   PubMed Web of Science ®Google Scholar
• Werner C, Pauli M, Doose S, et al. Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition. Brain. 2016;139(Pt 2):365–379. doi: 10.1093/brain/awv324.
   PubMedGoogle Scholar
• Saiz A, Dalmau J, Butler MH, et al. Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry. 1999;66(2):214–217. doi: 10.1136/jnnp.66.2.214.
   PubMed Web of Science ®Google Scholar
• Geis C, Weishaupt A, Hallermann S, et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain. 2010;133(11):3166–3180. doi: 10.1093/brain/awq253.
   PubMed Web of Science ®Google Scholar
• Sommer C, Weishaupt A, Brinkhoff J, et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet. 2005;365(9468):1406–1411. doi: 10.1016/S0140-6736(05)66376-3.
   PubMed Web of Science ®Google Scholar
• Irani SR. ‘Moonlighting’ surface antigens: a paradigm for autoantibody pathogenicity in neurology? Brain. 2016;139(Pt 2):304–306. doi: 10.1093/brain/awv364.
   PubMedGoogle Scholar
• Dinkel K, Meinck H-M, Jury KM, et al. Inhibition of ?-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol. 1998;44(2):194–201. doi: 10.1002/ana.410440209.
   PubMed Web of Science ®Google Scholar
• Raju R, Foote J, Banga JP, et al. Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol. 2005;175(11):7755–7762. doi: 10.4049/jimmunol.175.11.7755.
   PubMed Web of Science ®Google Scholar
• Ishida K, Mitoma H, Song S-Y, et al. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol. 1999;46(2):263–267. doi: 10.1002/1531-8249(199908)46:2<263::AID-ANA19>3.0.CO;2-0.
   PubMed Web of Science ®Google Scholar
• Takenoshita H, Shizuka-Ikeda M, Mitoma H, et al. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2001;70(3):386–389. doi: 10.1136/jnnp.70.3.386.
   PubMed Web of Science ®Google Scholar
• Vianello M, Vianello M, Bisson G, et al. Increased spontaneous activity of a network of hippocampal neurons in culture caused by suppression of inhibitory potentials mediated by anti-gad antibodies. Autoimmunity. 2008;41(1):66–73. doi: 10.1080/08916930701619565.
   PubMed Web of Science ®Google Scholar
• Stemmler N, Rohleder K, Malter MP, et al. Serum from a patient with GAD65 antibody-associated limbic encephalitis did not alter GABAergic neurotransmission in cultured hippocampal networks. Front Neurol. 2015 [cited 2023 Mar 20];6:189. doi: 10.3389/fneur.2015.00189.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Ishida K, Shizuka-Ikeda M, et al. Dual impairment of GABAA- and GABAB-receptor-mediated synaptic responses by autoantibodies to glutamic acid decarboxylase. J Neurol Sci. 2003;208(1-2):51–56. doi: 10.1016/s0022-510x(02)00423-9.
   PubMed Web of Science ®Google Scholar
• Manto MU, Hampe CS, Rogemond V, et al. Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. Orphanet J Rare Dis. 2011[cited 2023 Mar 20];6:3. doi: 10.1186/1750-1172-6-3.
   PubMed Web of Science ®Google Scholar
• Manto M, Honnorat J, Hampe CS, et al. Disease-specific monoclonal antibodies targeting glutamate decarboxylase impair GABAergic neurotransmission and affect motor learning and behavioral functions. Front Behav Neurosci. 2015;9:78. doi: 10.3389/fnbeh.2015.00078.
   PubMed Web of Science ®Google Scholar
• Geis C, Weishaupt A, Grünewald B, et al. Human Stiff-Person syndrome IgG induces anxious behavior in rats. Meuth S, editor. PLoS One. 2011;6(2):e16775. doi: 10.1371/journal.pone.0016775.
   PubMed Web of Science ®Google Scholar
• Hansen N, Grünewald B, Weishaupt A, et al. Human stiff person syndrome IgG-containing high-titer anti-GAD65 autoantibodies induce motor dysfunction in rats. Exp Neurol. 2013;239:202–209. doi: 10.1016/j.expneurol.2012.10.013.
   PubMed Web of Science ®Google Scholar
• Chuquisana O, Strippel C, Tröscher AM, et al. Complement activation contributes to GAD antibody-associated encephalitis. Acta Neuropathol. 2022;144(2):381–383. doi: 10.1007/s00401-022-02448-x.
   PubMed Web of Science ®Google Scholar
• Tröscher AR, Mair KM, Verdú de Juan L, et al. Temporal lobe epilepsy with GAD antibodies: neurons killed by T cells not by complement membrane attack complex. Brain. 2023;146(4):1436–1452. doi: 10.1093/brain/awac404.
   PubMed Web of Science ®Google Scholar
• Rocchi A, Sacchetti S, De Fusco A, et al. Autoantibodies to synapsin I sequestrate synapsin I and alter synaptic function. Cell Death Dis. 2019;10(11):864. doi: 10.1038/s41419-019-2106-z.
   PubMedGoogle Scholar
• Höltje M, Mertens R, Schou MB, et al. Synapsin-antibodies in psychiatric and neurological disorders: prevalence and clinical findings. Brain Behav Immun. 2017;66:125–134. doi: 10.1016/j.bbi.2017.07.011.
   PubMed Web of Science ®Google Scholar
• Ricken G, Schwaiger C, De Simoni D, et al. Detection methods for autoantibodies in suspected autoimmune encephalitis. Front Neurol. 2018;9:841. doi: 10.3389/fneur.2018.00841.
   PubMed Web of Science ®Google Scholar
• Waters P, Pettingill P, Lang B. Detection methods for neural autoantibodies. Handb Clin Neurol. 2016;133:147–163. doi: 10.1016/B978-0-444-63432-0.00009-8.
   Google Scholar
• Budhram A, Dubey D, Sechi E, et al. Neural antibody testing in patients with suspected autoimmune encephalitis. Clin Chem. 2020;66(12):1496–1509. doi: 10.1093/clinchem/hvaa254.
   PubMed Web of Science ®Google Scholar
• Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, et al. Autoimmune encephalitis misdiagnosis in adults. JAMA Neurol. 2023;80(1):30–39. doi: 10.1001/jamaneurol.2022.4251.
   PubMedGoogle Scholar
• Infantino M, Tampoia M, Fabris M, et al. Combining immunofluorescence with immunoblot assay improves the specificity of autoantibody testing for myositis. Rheumatology. 2019;58(7):1239–1244. doi: 10.1093/rheumatology/key451.
   PubMed Web of Science ®Google Scholar
• Chen JJ, McKeon A, Greenwood TM, et al. Clinical utility of antiretinal antibody testing. JAMA Ophthalmol. 2021;139(6):658–662. doi: 10.1001/jamaophthalmol.2021.0651.
   PubMed Web of Science ®Google Scholar
• Ruiz-García R, Martínez-Hernández E, Saiz A, et al. The diagnostic value of onconeural antibodies depends on how they are tested. Front Immunol. 2020;11:1482. doi: 10.3389/fimmu.2020.01482.
   PubMed Web of Science ®Google Scholar
• Zuliani L, Nosadini M, Gastaldi M, et al. Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations. Neurol Sci. 2019;40(10):2017–2030. doi: 10.1007/s10072-019-03930-3.
   PubMed Web of Science ®Google Scholar
• Tan EM, Feltkamp TEW, Smolen JS, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40(9):1601–1611. doi: 10.1002/art.1780400909.
   PubMedGoogle Scholar
• Gastaldi M, Zardini E, Scaranzin S, et al. Autoantibody diagnostics in neuroimmunology: experience from the 2018 Italian neuroimmunology association external quality assessment program. Front Neurol. 2019;10:1385. doi: 10.3389/fneur.2019.01385.
   PubMed Web of Science ®Google Scholar
• Masi G, Spagni G, Campetella L, et al. Assessing the role of a tissue-based assay in the diagnostic algorithm of autoimmune encephalitis. J Neuroimmunol. 2021;356:577601. doi: 10.1016/j.jneuroim.2021.577601.
   PubMed Web of Science ®Google Scholar
• Gastaldi M, Mariotto S, Giannoccaro MP, et al. Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study. Eur J Neurol. 2020;27(4):633–643. doi: 10.1111/ene.14139.
   PubMed Web of Science ®Google Scholar
• Woodhall M, Mgbachi V, Fox H, et al. Utility of live cell-based assays for autoimmune neurology diagnostics. J Appl Lab Med. 2022;7(1):391–393. doi: 10.1093/jalm/jfab133.
   PubMedGoogle Scholar
• van Coevorden-Hameete MH, de Bruijn MAAM, de Graaff E, et al. The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. Brain. 2019;142(6):1631–1643. doi: 10.1093/brain/awz094.
   PubMed Web of Science ®Google Scholar
• Thouin A, Gastaldi M, Woodhall M, et al. Comparison of N-methyl-d-aspartate receptor antibody assays using live or fixed substrates. J Neurol. 2021;268(5):1818–1826. doi: 10.1007/s00415-020-10329-0.
   PubMed Web of Science ®Google Scholar
• Cullen AE, Palmer-Cooper EC, Hardwick M, et al. Influence of methodological and patient factors on serum NMDAR IgG antibody detection in psychotic disorders: a meta-analysis of cross-sectional and case-control studies. Lancet Psychiatry. 2021;8(2):109–120. doi: 10.1016/S2215-0366(20)30432-6.
   PubMed Web of Science ®Google Scholar
• Lopez JA, Houston SD, Tea F, et al. Validation of a flow cytometry live Cell-Based assay to detect myelin oligodendrocyte glycoprotein antibodies for clinical diagnostics. J Appl Lab Med. 2022;7(1):12–25. doi: 10.1093/jalm/jfab101.
   PubMedGoogle Scholar
• Waters PJ, Pittock SJ, Bennett JL, et al. Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol. 2014;5(3):290–303. doi: 10.1111/cen3.12107.
   PubMedGoogle Scholar
• Ramberger M, Peschl P, Schanda K, et al. Comparison of diagnostic accuracy of microscopy and flow cytometry in evaluating N-Methyl-D-Aspartate receptor antibodies in serum using a live Cell-Based assay. Gelderblom M, editor. PLoS One. 2015;10(3):e0122037. doi: 10.1371/journal.pone.0122037.
   PubMed Web of Science ®Google Scholar
• Bien CG, Mirzadjanova Z, Baumgartner C, et al. Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome. Eur J Neurol. 2017;24(1):175–186. doi: 10.1111/ene.13180.
   PubMed Web of Science ®Google Scholar
• Dahm L, Ott C, Steiner J, et al. Seroprevalence of autoantibodies against brain antigens in health and disease: brain-Targeting autoantibodies. Ann Neurol. 2014;76(1):82–94. doi: 10.1002/ana.24189.
   PubMed Web of Science ®Google Scholar
• Gastaldi M, Thouin A, Franciotta D, et al. Pitfalls in the detection of N-methyl- d -aspartate-receptor (NMDA-R) antibodies. Clin Biochem. 2017;50(6):354–355. doi: 10.1016/j.clinbiochem.2016.11.023.
   PubMed Web of Science ®Google Scholar
• Ruiz-García R, Martínez-Hernández E, Joubert B, et al. Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Neurol Neuroimmunol Neuroinflamm. 2020;7:e658. doi: 10.1212/NXI.0000000000000658.
   PubMed Web of Science ®Google Scholar
• Muñoz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, et al. Neurologic syndromes related to anti-GAD65: clinical and serologic response to treatment. Neurol Neuroimmunol Neuroinflamm. 2020;7:e696. doi: 10.1212/NXI.0000000000000696.
   PubMed Web of Science ®Google Scholar
• Liu M, Ren H, Fan S, et al. Neurological autoimmunity associated with homer-3 antibody: a case series from China. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1077. doi: 10.1212/NXI.0000000000001077.
   PubMed Web of Science ®Google Scholar
• Höftberger R, Sabater L, Velasco F, et al. Carbonic anhydrase-related protein VIII antibodies and paraneoplastic cerebellar degeneration. Neuropathol Appl Neurobiol. 2014;40(5):650–653. doi: 10.1111/nan.12118.
   PubMed Web of Science ®Google Scholar
• Tampoia M, Zucano A, Antico A, et al. Diagnostic accuracy of different immunological methods for the detection of antineuronal antibodies in paraneoplastic neurological syndromes. Immunol Invest. 2010;39(2):186–195. doi: 10.3109/08820130903513431.
   PubMed Web of Science ®Google Scholar
• Cunquero M, Aguilar E, Loza-Alvarez P, et al. Hippocampal neuronal cultures to detect and study new pathogenic antibodies involved in autoimmune encephalitis. J Vis Exp. 2022;184:e63829. doi: 10.3791/63829-v.
   Web of Science ®Google Scholar
• Tsiortou P, Alexopoulos H, Dalakas MC. GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. Ther Adv Neurol Disord. 2021;14:17562864211003486. doi: 10.1177/17562864211003486.
   Web of Science ®Google Scholar
• Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13(3):276–286. doi: 10.1016/S1474-4422(13)70299-0.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Li M, Fujii M, et al. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology. 2001;57(5):780–784. doi: 10.1212/wnl.57.5.780.
   PubMed Web of Science ®Google Scholar
• Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci. 2001;184(2):101–122. doi: 10.1016/s0022-510x(00)00501-3.
   PubMed Web of Science ®Google Scholar
• Gadoth A, Zekeridou A, Klein CJ, et al. Elevated LGI1-IgG CSF index predicts worse neurological outcome. Ann Clin Transl Neurol. 2018;5(5):646–650. doi: 10.1002/acn3.561.
   PubMed Web of Science ®Google Scholar